Menu Search
Equities

Purple Biotech Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1YI:MUN

Purple Biotech Ltd

Actions
  • Price (EUR)6.00
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.6147
Data delayed at least 15 minutes, as of Sep 23 2024 07:24 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

  • Revenue in USD (TTM)0.00
  • Net income in USD-3.25m
  • Incorporated1968
  • Employees9.00
  • Location
    Purple Biotech Ltd4 Oppenheimer St., Science ParkREHOVOT 7670104IsraelISR
  • Phone+972 39333121
  • Fax+972 35097196
  • Websitehttps://purple-biotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.